You are here
TSRL, INC.
UEI: TP74UMNGJDJ1
# of Employees: 9
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
Amount: $998,521.00The objective of this grant is the preclinical development of MRS-2541, a novel antibiotic structure targeting Gram+ bacteria by a new mechanism of action. MRS-2541 inhibits bacterial methionyl- tRNA ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
Amount: $299,999.00Abstract Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is lt0.03%, but with significant mortality in the young ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis
Amount: $1,632,248.00Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Sepsis represents a major health issue, which claims over 270,000 l ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
Amount: $1,999,466.00Abstract Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is lt0.03%, but with significant mortality in the young ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Novel, Safe, Efficacious Heparin Reversal
Amount: $394,392.00Abstract Anticoagulants and their reversal agents are key components of standard of care for managing thrombosis. Heparin in particular is used for thrombosis prevention in multiple clinical indicatio ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease
Amount: $299,620.00Abstract Overactive bladder (OB) is a disease that afflicts both men and women and is driven by the aging population with a prevalence estimated as high as 39% in the US and 45% for all women over 65. ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Microneedle Delivery of Zanamivir for Treatment of Influenza
Amount: $2,922,334.00Abstract Yearly influenza epidemics strike millions of people, causing up to 500,000 deaths. Fatality caused by most seasonal influenza viruses is andlt;0.03%, but with significant mortality in the yo ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections
Amount: $569,780.00Abstract Bronchiectasis is a lung pathology characterized by a permanent dilation of the bronchi and is associated with a chronic cough, sputum production and recurrent respiratory infections. Cystic ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
Amount: $572,526.00Abstract Yearly influenza epidemics strike millions of peoplecausing up todeathsFatality caused by most seasonal influenza viruses is ltbut with significant mortality in the young and the elderly popu ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections
Amount: $2,954,680.00The objective of this research is to develop a novel antibiotic targeting Gram positive bacteriawith an initial clinical indication of acute bacterial skin and skin structure infectionsABSSSIThe resea ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health